Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Northwell Health
Sponsor:
Collaborator:
Feinstein Institute for Medical Research
Information provided by (Responsible Party):
John A. Boockvar, Feinstein Institute for Medical Research
ClinicalTrials.gov Identifier:
NCT01269853
First received: December 22, 2010
Last updated: July 25, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2017
  Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)